Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up - European Society for Medical Oncology (ESMO)
The estimated overall incidence of acute lymphoblastic leukaemia and lymphoblastic lymphoma in Europe is 1.28 per 1 000 000 individuals annually, with significant age-related variations. This figure qualifies ALL as a rare disease in adults, making assessment and care at qualified centres highly desirable. The new ESMO Clinical Practice Guidelines provide up-to-date information on the management of acute lymphoblastic leukaemia, and include recommendations for diagnosis and pathology/molecular biology, staging and risk assessment as well as detailed treatment strategies for early and advanced disease.